Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent

  title={Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent},
  author={Alex A. Adjei},
  journal={Clinical Cancer Research},
  pages={4276s - 4280s}
  • A. Adjei
  • Published 15 June 2004
  • Biology, Chemistry, Medicine
  • Clinical Cancer Research
Pemetrexed (ALIMTA, LY231514, MTA) is a novel antimetabolite that inhibits at least three enzymes involved in the folate pathway. These enzymes are thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has demonstrated clinical activity in non-small cell lung cancer as well as in a broad array of other solid tumors, including mesothelioma, breast, colorectal, bladder, cervical, gastric and pancreatic cancer. In non-small cell lung cancer… 
The evolving role of pemetrexed (Alimta) in lung cancer.
Pemetrexed is a multitargeted antifolate that inhibits several folate-dependent enzymes that play roles in purine and pyrimidine synthesis that appears to possess activity in extensive stage small cell lung cancer and can be combined with thoracic radiation therapy, but more data are needed to evaluate the potential advantage pemetrexe may have in this setting.
Clinical studies of pemetrexed and gemcitabine combinations.
  • A. Adjei
  • Biology, Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2006
A recently published randomized trial of different sequences has identified the sequence of pemetrexed on day 1 followed by gemcitabine on day 8, every 21 days as the most efficacious and least toxic sequence.
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications
The history of antifolates that led to the development of pemetrexed is traced and the unique properties of this agent are described, including its very rapid conversion to active polyglutamate derivatives in cells and its marked sensitivity to the level of physiologic folates in cells.
Pemetrexed (Alimta) in small cell lung cancer.
Pembrexed/platinum combinations appear active in ES-SCLC based on objective response rates observed in a randomized phase II trial, and preliminary data indicates that full doses of carboplatin/pemetrexed can be administered with thoracic radiation therapy, supporting a future clinical trial initiative in LS- SCLC.
Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed
The first goal of this review is to briefly review pemetrexed’s mechanism of action, resistance patterns, toxicity profile, and pharmacokinetics, and to review the clinical trials that led to its use in NSCLC.
Pemetrexed Therapy for Malignant Pleural Mesothelioma
Pemetrexed is a promising new drug for the treatment of solid malignancies, most notably MPM, which has antitumor activity in solid tumors such as lung, colorectal, and cervical.
Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells
It is found that MTA induced DNA damage and mitochondrial-mediated apoptosis in human melanoma cells in vitro and that the associated apoptosis was both caspase-dependent and –independent and p53-mediated.
The current state of pemetrexed in ovarian cancer
The activity of single agent pemetrexed in platinum-resistant patients is worth exploring and biomarker-driven randomized, clinical trials and patient selection are key for the future development of pemet Rexed.
Emerging role of pemetrexed in ovarian cancer
According to clinical results, it appears reasonable to explore the combination of pemetrexed with other cytotoxic agents and also with targeted therapies in relapsed ovarian cancer patients.
Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions
Findings suggest that a single dose of dexamethasone 20 mg may be an alternative premedication regimen in patients with metastatic non small cell lung cancer receiving pemetrexed or pemetrezed-based chemotherapy.